167 related articles for article (PubMed ID: 38433568)
1. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight.
Damare R; Engle K; Kumar G
Phytother Res; 2024 May; 38(5):2406-2447. PubMed ID: 38433568
[TBL] [Abstract][Full Text] [Related]
2. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
Wang X; Xu L; Lao Y; Zhang H; Xu H
Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
[TBL] [Abstract][Full Text] [Related]
3. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.
Gusenbauer S; Vlaicu P; Ullrich A
Oncogene; 2013 Aug; 32(33):3846-56. PubMed ID: 23045285
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics.
Shetty SR; Yeeravalli R; Bera T; Das A
Anticancer Agents Med Chem; 2021; 21(14):1783-1792. PubMed ID: 33355057
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
[TBL] [Abstract][Full Text] [Related]
6. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
Zhou Y; Takahashi JI; Sakurai H
Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
[TBL] [Abstract][Full Text] [Related]
7. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF
Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767
[TBL] [Abstract][Full Text] [Related]
8. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.
Wu M; Zhang P
Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425
[TBL] [Abstract][Full Text] [Related]
9. EGFR-TKIs resistance via EGFR-independent signaling pathways.
Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
[TBL] [Abstract][Full Text] [Related]
10. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
Liang Y; Zhang T; Zhang J
Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
[TBL] [Abstract][Full Text] [Related]
11. Review on EGFR Inhibitors: Critical Updates.
Singh D; Attri BK; Gill RK; Bariwal J
Mini Rev Med Chem; 2016; 16(14):1134-66. PubMed ID: 26996617
[TBL] [Abstract][Full Text] [Related]
12. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
Nandi S; Dey R; Samadder A; Saxena A; Saxena AK
Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823
[TBL] [Abstract][Full Text] [Related]
13. Naturally Occurring Compounds as Potential Inhibitors of Epidermal Growth Factor Receptors (EGFRs).
Oktavia L; Fuad AM; Senjaya SK; Yuliyawati Y
Comb Chem High Throughput Screen; 2023; 26(6):1093-1107. PubMed ID: 35894461
[TBL] [Abstract][Full Text] [Related]
14. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
Wykosky J; Fenton T; Furnari F; Cavenee WK
Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
17. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
18. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
19. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
